Shah Wealth Advisors LLC increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 61.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,328 shares of the company’s stock after acquiring an additional 42,268 shares during the quarter. CRISPR Therapeutics comprises 1.2% of Shah Wealth Advisors LLC’s holdings, making the stock its 21st biggest position. Shah Wealth Advisors LLC owned 0.12% of CRISPR Therapeutics worth $6,159,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. EagleClaw Capital Managment LLC boosted its stake in CRISPR Therapeutics by 77.2% in the third quarter. EagleClaw Capital Managment LLC now owns 30,220 shares of the company’s stock valued at $1,672,000 after acquiring an additional 13,170 shares in the last quarter. Moors & Cabot Inc. increased its position in shares of CRISPR Therapeutics by 9.5% during the third quarter. Moors & Cabot Inc. now owns 7,373 shares of the company’s stock worth $408,000 after purchasing an additional 641 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of CRISPR Therapeutics by 178.8% during the third quarter. Russell Investments Group Ltd. now owns 212,645 shares of the company’s stock worth $11,764,000 after purchasing an additional 136,379 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of CRISPR Therapeutics by 2.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 24,136 shares of the company’s stock worth $1,338,000 after purchasing an additional 658 shares in the last quarter. Finally, Privium Fund Management B.V. lifted its holdings in shares of CRISPR Therapeutics by 8.9% during the 3rd quarter. Privium Fund Management B.V. now owns 48,974 shares of the company’s stock valued at $2,709,000 after purchasing an additional 4,000 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. Citizens Jmp reissued a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Piper Sandler restated an “overweight” rating and set a $110.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price target on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $72.93.
Check Out Our Latest Research Report on CRISPR Therapeutics
CRISPR Therapeutics Price Performance
Shares of NASDAQ:CRSP opened at $42.24 on Monday. CRISPR Therapeutics AG has a twelve month low of $41.75 and a twelve month high of $63.45. The company’s 50 day moving average is $52.09 and its 200 day moving average is $52.54. The company has a current ratio of 16.21, a quick ratio of 16.21 and a debt-to-equity ratio of 0.36. The company has a market cap of $4.10 billion, a PE ratio of -8.91 and a beta of 1.92.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The business had revenue of $12.67 million for the quarter, compared to analysts’ expectations of $14.75 million. CRISPR Therapeutics’s revenue was up 1311.1% on a year-over-year basis. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -4.54 EPS for the current year.
Insider Buying and Selling at CRISPR Therapeutics
In other news, CEO Samarth Kulkarni sold 47,837 shares of the stock in a transaction on Monday, October 19th. The shares were sold at an average price of $49.78, for a total value of $2,381,325.86. Following the sale, the chief executive officer owned 311,899 shares in the company, valued at $15,526,332.22. This represents a 13.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James R. Kasinger sold 1,040 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total transaction of $51,230.40. Following the transaction, the general counsel directly owned 95,857 shares of the company’s stock, valued at approximately $4,721,915.82. This trade represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 93,558 shares of company stock worth $4,881,663 over the last ninety days. 5.20% of the stock is owned by insiders.
CRISPR Therapeutics Profile
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
Read More
- Five stocks we like better than CRISPR Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
